@article {1917,
	title = {Prediction of MMP-9 Polymorphism Impacts on MDR-TB by Molecular Simulation and Network Interaction},
	journal = {Pharmacognosy Journal},
	volume = {14},
	year = {2022},
	month = {December 2022},
	pages = {833-841},
	type = {Research Article },
	chapter = {833},
	abstract = {<p class="rtejustify">MMP-9 overexpression is associated with a poor outcome in MDR-TB patients, indicating that MMP-9 is a suitable target for MDR-TB therapy. MMP-9 also includes SNPs that occur at inhibitor binding areas as well as zinc ions. As a result of polymorphisms, the usage of MMP-9 inhibitors for MDR-TB might vary. Through molecular simulation, it has been found that the mutant MMP-9 has a larger cavity and a more lipophilic surface. The docking tests revealed that EGTA had the least amount of binding energy to both wild-type and mutant MMP-9. The wildtype MMP-9 can bind zinc when EGTA is in the active site. This shows that using EGTA to chelate Zn is only partially successful. However, the binding energy of EGTA at the active site suggests that it may be a competitor to MMP-9 substrates. On the other hand, Zn is not involved in the interaction of the mutant MMP-9-EGTA complex.</p>
},
	keywords = {Gene polymorphism, Matrix metalloproteinase 9, Molecular simulation., Multidrug resistant TB},
	doi = {10.5530/pj.2022.14.176},
	author = {Anse Diana Valentiene Messah and Sawitri Darmiati and Cleopas Marthin Rumende and Retno Ariza Soemarwoto and Joedo Prihartono and Asmarinah and Fadilah Fadilah and Aisyah Fitriannisa Prawiningrum}
}
